biostudies-literatureTeo CFNational Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthNational Institute of General Medical SciencesNIGMS NIH HHS1198-1208https://www.ebi.ac.uk/biostudies/studies/S-EPMC5884396biostudies-literatureUnknown26(11)Previous studies utilizing PUGNAc, the most widely used β-N-acetylglucosaminidase (OGA) inhibitor to increase global O-N-acetylglucosamine (GlcNAc) levels, have reported a variety of effects including insulin resistance as a direct result of elevated O-GlcNAc levels. The notion of OGA inhibition causing insulin resistance was not replicated in studies in which elevated global O-GlcNAc levels were achieved using two other OGA inhibitors. Related to insulin action, work by others has suggested that O-GlcNAc elevation may inhibit the anti-apoptotic action of insulin. Thus, we examined the pro-survival action of insulin upon serum deprivation in the presence of PUGNAc as well as two selective OGA inhibitors (GlcNAcstatin-g and Thiamet-G), and a selective lysosomal hexosaminidase inhibitor (INJGlycobiologyDissecting PUGNAc-mediated inhibition of the pro-survival action of insulin.PMC5884396P41 GM103490P41GM103490R01DK075069El-Karim EGTeo CFWells LfalseDissecting PUGNAc-mediated inhibition of the pro-survival action of insulin.Previous studies utilizing PUGNAc, the most widely used β-N-acetylglucosaminidase (OGA) inhibitor to increase global O-N-acetylglucosamine (GlcNAc) levels, have reported a variety of effects including insulin resistance as a direct result of elevated O-GlcNAc levels. The notion of OGA inhibition causing insulin resistance was not replicated in studies in which elevated global O-GlcNAc levels were achieved using two other OGA inhibitors. Related to insulin action, work by others has suggested that O-GlcNAc elevation may inhibit the anti-apoptotic action of insulin. Thus, we examined the pro-survival action of insulin upon serum deprivation in the presence of PUGNAc as well as two selective OGA inhibitors (GlcNAcstatin-g and Thiamet-G), and a selective lysosomal hexosaminidase inhibitor (INJ2016-01-01T00:00:00Z2016 Nov2025-04-04T19:34:24.203Z2019-03-26T23:50:11ZS-EPMC58843962707281410.1093/glycob/cww043